SMMT Q2 2021 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57,000-66.5% YoY

Gross Profit

$57,000100.0% margin

Operating Income

-$24M-41631.6% margin

Net Income

-$24M-42835.1% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-70.3%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$146M

Total Liabilities

$26M

Stockholders' Equity

$119M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57,000	$170,000	-66.5%
Gross Profit	$57,000	$170,000	-66.5%
Operating Income	-$24M	-$12M	-91.5%
Net Income	-$24M	-$15M	-60.3%

Revenue Segments

License and Service

$57,000100%

Geographic Segments

Latin America

$57,000100%